§ Mr. Gordon Brownasked the Secretary of State for Social Services (1) if he will estimate the proportion of families (a) with and (b) without children taking up their entitlement to rent rebates, rent allowance and rate rebates for the latest date available.
(2) if he will estimate the current take-up of the housing benefit allowance.
§ Dr. Boyson[pursuant to his replies, 14 November 1983, c. 334, and 9 December 1983, c. 293]: The data for 1983 have now been analysed and the information requested is in the following table.
567W
Yellow card report(1) Industry report(2) Others (3) Deaths (included in columns 1–3) 1964 84 15 20 21 1965 409 36 50 51 1966 184 37 24 49 1967 171 21 46 46 1968 190 27 44 47 1969 203 43 35 46 1970 188 29 32 40 1971 139 44 43 45 1972 215 38 51 51 1973 236 42 19 46
Yellow card report (1) Industry report (2) Others(3) Deaths (included in columns 1–3) 1974 433 75 54 67 1975 274 61 95 99 1976 472 84 49 54 1977 1,072 84 60 61 1978 1,679 242 69 61 1979 1,812 314 106 63 1980 2,309 594 84 55 1981 4,017 309 182 88 1982 3,021 255 309 111 1983 3,154 336 276 127 It is important to note that a report does not necessarily demonstrate a causal relationship between the reaction and the drugs concerned.
§ Mr. Ashleyasked the Secretary of State for Social Services (1) whether the Committee on Safety of Medicines was sent a copy of Ciba-Geigy's internal assessment of the safety of butazolidin and tanderil dated September 1982; when it was sent; and what was the Committee's response;
(2) pursuant to the reply of 15 February, Official Report, c. 234, from whom the Committee on Safety of Medicines has obtained information to help it with its review of the safety of products containing phenylbutazone and oxyphenbutazone; if it consulted drug safety bodies in other countries and what is the total number of (a) adverse reactions and (b) deaths reported to them from all sources.
§ Mr. Kenneth Clarke[pursuant to his reply, 27 February 1984, c. 75–76]: The Committee on Safety of Medicines—CSM—obtained obtained its information in respect of the products referred to from adverse reactions reports submitted to it by doctors, from published reports in the professional literature and from the company concerned. The company's own internal assessment of the safety of butazolidin and tanderil was received by the CSM in December 1983 and used in its own review of the safety of these products. The secretariat of the CSM has kept in close contact with other drug regulatory authorities during this review.
The figures requested of adverse reactions and deaths fom 1964 to date are as follows:
Total reports registered Deaths Phenylbutazone 1,693 445 Oxyphenbutazone 508 131 It is important to note that a report does not necessarily demonstrate a causal relationship between the reaction and the drug concerned.
§ Mr. Ashleyasked the Secretary of State for Social Services how many non-steroidal anti-inflammatory drugs are currently available to be prescribed; what are their names; and approximately how many prescriptions a year are issued for this category of drug.
Mr. Kenneth Clark[pursuant to his reply, 27 February 1984, c. 75–76]: Twenty-one non-steroidal anti-inflammatory drugs are available on prescription only. Their names are as follows. In 1982, the last year for which figures are available, approximately 16.5 million prescriptions were issued for these drugs. Figures have not 568W been included for other drugs in this class—for example, aspirin—which are obtainable over the counter as well as on prescription.
- Azapropazone
- Diclofenac Sodium
- Diflunisal
- Fenbufen
- Fenclofenac
- Fenoprofen
- Feprazone
- Flufenamic Acid
- Flurbiprofen
- Ibuprofen
- Indomethacin
- Indoprofen
- Ketoprofen
- Mefenamic Acid
- Naproxen
- Oxyphenbutazone
- Phenylbutazone
- Piroxicam
- Sulindac
- TiaprofenicAcid
- Tolmetin
§ Mr. Ashleyasked the Secretary of State for Social Services, pursuant to the reply of 13 December 1983, Official Report, c. 443–44 if he will categorise the 442 and 131 reports associated with products containing phenylbutazone and oxyphenbutazone, respectively, according to the year the report was received; and whether the source was a general practitioner sending in a yellow card, one of the companies producing the products, or any other source.
§ Mr. Kenneth Clarke[pursuant to his reply, 27 February 1984, c. 75–76]: The information requested is as follows. In the case of both tables it is important to bear in mind that a report does not necessarily imply a causal relationship with the drug.
PHENYIMUTAZONE Year Yellow card from a medical practitioner Company report Other* 1964 6 4 6 1965 15 4 18 1966 12 13 14 1967 5 6 19 1968 8 4 11 1969 10 4 9 1970 8 1 10 1971 9 5 17 1972 13 1 15 1973 15 3 9 1974 8 1 14 1975 12 4 32 1976 7 1 18 1977 7 — 12 1978 4 3 8 1979 — 2 14 1980 4 2 0 1981 1 2 2 1982 3 1 2 1983 4 — 0 *Includes deaths reported on coroners' certificate, reports in professional journals etc.
569W
OXYPHENBUTAZONE Year Yellow card from a medical practitioner Company report Other* 1964 3 — 2 1965 5 2 1 1966 3 2 —
Year Yellow card from a medical practitioner Company report Other* 1967 4 2 3 1968 3 3 4 1969 4 4 3 1970 2 1 1 1971 4 — 4 1972 3 3 4 1973 6 — 2 1974 5 2 5 1975 8 — 7 1976 3 — 1 1977 3 2 2 1978 3 — 4 1979 — 1 2 1980 2 — — 1981 1 1 — 1982 1 — — 1983 — — — *Includes deaths reported on coroners' certificate, reports in professional journals etc.